Navigation Links
YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
Date:12/6/2010

al Officer and Vice President, Regulatory Affairs, Dr. Gregg Smith, Vice President, Australian Operations and Dr. Chris Burns, Director, Research, YM BioSciences Australia.

Analysts and professional investors may also participate in the meeting by conference call. A webcast of the meeting will be available on YM's website: www.ymbiosciences.com.

Meeting/Conference Call Details: DATE: December 6, 2010 TIME: 12:30 pm Eastern Time DIAL IN NUMBER: (647) 427-7450 or (888) 231-8191 MEETING LOCATION: Hilton Orlando, Lake Sheen A Room

About CYT387:

CYT387 is an inhibitor of the kinase enzymes JAK1 and JAK2, which have been implicated in a family of hematological conditions known as myeloproliferative neoplasms, including myelofibrosis, and as well in numerous other disorders including indications in hematology, oncology and inflammatory diseases. Myelofibrosis is a chronic debilitating disease in which a patient's bone marrow is replaced by scar tissue and for which treatment options are limited or unsatisfactory. The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CYT387 for the treatment of myelofibrosis.

YM BioSciences retains the global commercialization rights to CYT387.

About YM BioSciences

YM BioSciences Inc. is a drug development company advancing three clinical-stage products: CYT387, a small molecule, dual inhibitor of JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody; and CYT997, a potent vascular disrupting agent (VDA).

CYT387 is an orally administered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis with positive interim safety and activity data reported at the American Society of Hematology (ASH
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
2. Ardea Biosciences to Present at Two Upcoming Investor Conferences
3. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
4. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
5. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
6. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
7. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
8. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
9. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
10. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
11. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , ... July 02, 2015 , ... ... and manufacturing of surgical instruments in Orthopedics, announced today the acquisition of ... the world's largest provider of surgical instruments to the Spine Industry. The acquisition ...
(Date:7/1/2015)...   Decision Resources Group finds that ... are its oral administration, alternative mechanism of action, ... rheumatologists. Otezla was the first oral therapy specifically ... psoriatic arthritis in the United States ... conventional oral treatments including disease-modifying antirheumatic drugs (DMARDs), ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest will ask ... to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will ... and a period of expert mentorship from a senior industry figure drawn from the ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... July 25, 2011   ... articles on SciVerse ScienceDirect   ... information products and services, today announced the availability of an ... and mobile apps, on SciVerse Applications beta . The ...
... International, Inc. (Nasdaq: BDSI ) announced today ... of its Phase 3 clinical trial assessing the efficacy ... moderate to severe chronic pain, signifying completion of the ... very pleased to have brought to completion our Phase ...
... journal Nature Physics , the academics, who discovered ... in 2004, have revealed more about its electronic properties. ... already looking at ways to build devices such as ... from the creators of the material promises to accelerate ...
Cached Biology Technology:iSpeech® Develops Audio Reader for Elsevier's SciVerse Applications 2iSpeech® Develops Audio Reader for Elsevier's SciVerse Applications 3iSpeech® Develops Audio Reader for Elsevier's SciVerse Applications 4BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 2BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study 3Graphene's 'quantum leap' takes electronics a step closer 2
(Date:6/17/2015)... BEACH GARDENS, Fla. , June 17, 2015 ... management solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... fast casual sandwich chain, to increase security, improve ... Crossmatch fingerprint readers enable instant, non-repudiable identity confirmation ...
(Date:6/16/2015)... June 16, 2015  With the increasing number and ... a top concern. The recent compromise of Federal ... for strong authentication within government agencies. HYPR ... one-time password (OTP) authenticator, has been submitted for testing ... Level 3 validation for tamper proofing. ...
(Date:6/16/2015)... 16, 2015 Fingerprint Cards (FPC) raises ... it will amount to at least 340 MSEK to that ... rapid increase in market growth and orders received the revenue ... that revenue for 2015 will exceed 1,500 MSEK to an ... 2,200 MSEK. Due to receipt of orders of ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... be outside the box: A briefcase-sized kit is carried to ... The search is for microorganisms that could infect and kill ... If the equipment in the box finds the pathogen, ... and accurate are key. That,s what scientists plan to ...
... Institute of Technology (Caltech) and the University of California ... modeling and Caltech experimental data to show just how ... proteins. Their insights were recently published in the ... National Academy of Sciences (PNAS). The paper ...
... Graz, Austria Current research suggests that a new ... in archived tissue samples. The related report by ... in archival tissues from colorectal cancer patients using quantitative ... of The Journal of Molecular Diagnostics . ...
Cached Biology News:Portable kit may 1 day detect plant disease before disastrous outbreak 2Portable kit may 1 day detect plant disease before disastrous outbreak 3Caltech and UCSD researchers shed light on how proteins find their shapes 2New technique for cancer screening 2
...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z35,347-7) ...
... are fast multi-channel pipetting platforms consisting of ... with a multi-channel head and a robotic ... with true parallel processing of sample plates ... with the Freedom EVOware program. ...
... are fast multi-channel pipetting platforms consisting of ... with a multi-channel head and a robotic ... with true parallel processing of sample plates ... with the Freedom EVOware program. ...
Biology Products: